Nyxoah SA (NYXH) Q3 2026 Earnings Call Highlights: U.S. ...
Nyxoah SA (NYXH) posted 29% sequential U.S. revenue growth and strong AXIS study results, but trimmed its 2026 outlook as it awaits FDA review of the Genio CCC indication. Related Stocks: NYXH ,